siponimod.tablets

Effects and efficacy:
It is suitable for the treatment of relapsing multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
Usage and Dosage:
Recommended dose: Treatment must be started with the starting dose package, and the recommended daily dose should be taken once a day in the morning (on an empty stomach or with food). Patients with CYP2C9 *1*1 or *1*2 or *2*2 genotype: The titration period lasts for 5 days, and the dose titration scheme is as follows: 0.25 mg once a day on the 1st and 2nd days, 0.5 mg (2 tablets of 0.25 mg) once a day on the 3rd day, 0.75 mg (3 tablets of 0.25 mg) once a day on the 4th day, 1.25 mg (5 tablets of 0.25 mg) once a day on the 5th day, and the maintenance dose of 2 mg (1 tablet of 2 mg) of siponimod is reached and started on the 6th day, once a day. Patients with CYP2C9 *2*3 or *1*3 genotype: The titration period lasts for 4 days, and the dose titration scheme is as follows: 0.25 mg once daily on days 1 and 2, 0.5 mg (2 tablets of 0.25 mg) once daily on day 3, 0.75 mg (3 tablets of 0.25 mg) once daily on day 4, and the maintenance dose of 1 mg (4 tablets of 0.25 mg) of siponimod once daily is reached and started on day 5. Please take the whole tablet, do not break, crush or chew siponimod tablets. Siponimod is a drug that needs to be taken orally for a long time, and it is very important to take it as prescribed by the doctor. If siponimod maintenance treatment is interrupted for 4 or more consecutive daily doses, a new starting dose package is required to restart siponimod treatment. Dose interruptions caused by missing 3 consecutive daily doses do not require re-titration, but treatment should be continued at the maintenance dose. If treatment is stopped midway, re-titration or blood testing may be required. Monitoring of the first dose in patients with existing heart disease Since the initiation of siponimod treatment can cause a decrease in heart rate (HR), it is recommended to monitor for 6 hours after the first dose for patients with sinus bradycardia [HR less than 55 beats/minute (bpm)], first-degree or second-degree [Mobitz type I] AV block, and a history of myocardial infarction or heart failure. If any of the following abnormalities occur 6 hours after administration (even if asymptomatic), monitoring should continue until the abnormality is eliminated. HR <45bpm; The heart rate 6 hours after administration is the lowest value after administration, indicating that the maximum pharmacodynamic effect on the heart may not have been achieved; ECG 6 hours after administration shows new second-degree or higher AV block.
Drug contraindications:
Contraindicated if allergic to this product
Related dosage forms:
Tablets